Every GLP-1 Drug Approved in 2026 (Plus the Pipeline)
Every FDA-approved GLP-1 receptor agonist in 2026 — semaglutide, tirzepatide, liraglutide, dulaglutide, exenatide, lixisenatide and the pipeline — with brand names, doses and indications.
The GLP-1 class has gone from one approved drug in 2005 (exenatide) to a dozen branded products by 2026, spanning daily and weekly injections, oral peptides and the newest oral small-molecule GLP-1. This is the complete list — every FDA-approved GLP-1 receptor agonist in 2026, plus the dual / triple agonists and the pipeline drugs reading out in the next 12–24 months.
FDA-approved GLP-1 receptor agonists (single GLP-1 target)
Semaglutide
The most prescribed GLP-1 in the world.
| Brand | Form | Doses | Indication | Approval |
|---|---|---|---|---|
| Ozempic | Weekly subcutaneous injection | 0.25 / 0.5 / 1.0 / 2.0 mg | Type 2 diabetes | 2017 |
| Wegovy | Weekly subcutaneous injection | 0.25 / 0.5 / 1.0 / 1.7 / 2.4 mg + Wegovy HD 7.2 mg | Chronic weight management; CV risk reduction; MASH (added 2024–25) | 2021 (weight) |
| Rybelsus | Once-daily oral tablet | 3 / 7 / 14 mg | Type 2 diabetes | 2019 |
| Wegovy oral | Once-daily oral tablet | 0.25 – 25 mg | Chronic weight management | December 2025 |
Maker: Novo Nordisk. Trial programs: SUSTAIN (T2D), STEP (obesity), PIONEER (oral), SELECT (CV outcomes).
Liraglutide
The first GLP-1 approved for weight management.
| Brand | Form | Doses | Indication | Approval |
|---|---|---|---|---|
| Victoza | Daily subcutaneous injection | 0.6 / 1.2 / 1.8 mg | Type 2 diabetes | 2010 |
| Saxenda | Daily subcutaneous injection | 0.6 / 1.2 / 1.8 / 2.4 / 3.0 mg | Chronic weight management | 2014 |
Maker: Novo Nordisk.
Dulaglutide
| Brand | Form | Doses | Indication | Approval |
|---|---|---|---|---|
| Trulicity | Weekly subcutaneous injection | 0.75 / 1.5 / 3.0 / 4.5 mg | Type 2 diabetes | 2014 |
Maker: Eli Lilly. CV benefit shown in REWIND.
Exenatide
The original GLP-1 — historically based on a peptide from the saliva of the Gila monster.
| Brand | Form | Doses | Indication | Approval |
|---|---|---|---|---|
| Byetta | Twice-daily subcutaneous | 5 / 10 mcg | Type 2 diabetes | 2005 |
| Bydureon | Weekly subcutaneous | 2 mg | Type 2 diabetes | 2012 |
Maker: AstraZeneca.
Lixisenatide
| Brand | Form | Doses | Indication | Approval |
|---|---|---|---|---|
| Adlyxin | Daily subcutaneous | 10 / 20 mcg | Type 2 diabetes | 2016 |
Maker: Sanofi. Less commonly prescribed.
Albiglutide (discontinued)
Brand: Tanzeum. Weekly GLP-1 by GSK. Withdrawn from US market in 2018 for commercial reasons, not safety.
Dual receptor agonists (GLP-1 + GIP)
Tirzepatide
The dual GLP-1 / GIP agonist that surpassed single-receptor drugs on average weight loss.
| Brand | Form | Doses | Indication | Approval |
|---|---|---|---|---|
| Mounjaro | Weekly subcutaneous | 2.5 / 5 / 7.5 / 10 / 12.5 / 15 mg | Type 2 diabetes | 2022 |
| Zepbound | Weekly subcutaneous (pens, KwikPen, vials) | Same dose range | Chronic weight management; OSA (added 2024) | 2023 (weight) |
Maker: Eli Lilly.
Oral small-molecule GLP-1 agonists
Orforglipron
Brand: Foundayo (Eli Lilly). The first GLP-1 to enter the body as a small molecule rather than a peptide.
- Form: Once-daily oral tablet
- Doses: 0.8 mg – 17.2 mg (six strengths)
- Indication: Chronic weight management; T2D (separate filing)
- Approval: 2026 — under FDA's National Priority Voucher program
- Why it matters: Can be taken with or without food, at any time of day; no fasting window or empty-stomach requirement like oral Wegovy
- Trial weight loss: ~12.4% body weight at highest dose
- Cash pay: From $149/month via LillyDirect; ~$25/month with commercial coverage and copay card
Combination products
| Brand | Components | Form | Indication |
|---|---|---|---|
| Soliqua | Lixisenatide + insulin glargine | Daily injection | Type 2 diabetes |
| Xultophy | Liraglutide + insulin degludec | Daily injection | Type 2 diabetes |
Sanofi and Novo Nordisk respectively.
Pipeline: drugs not yet approved
Retatrutide (Eli Lilly)
Triple agonist: GLP-1 / GIP / glucagon. Phase 2 results showed up to 24.2% weight loss at 48 weeks (NEJM, 2023). Phase 3 (TRIUMPH program) reading through 2026. NDA expected late 2026; approval projected ~2027–2028. See our deep Retatrutide guide.
Survodutide (Boehringer Ingelheim / Zealand Pharma)
Dual GLP-1 / glucagon. Phase 3 ongoing for obesity, MASH and T2D.
Cagrilintide / CagriSema (Novo Nordisk)
Cagrilintide is an amylin analog; combined with semaglutide ("CagriSema") it has shown additive weight loss in Phase 2/3 trials. Phase 3 read-outs expected 2026.
Pemvidutide (Altimmune)
Dual GLP-1 / glucagon. In Phase 2/3 for obesity and MASH.
Danuglipron (Pfizer)
Oral non-peptide GLP-1 — Pfizer's small-molecule entry. Development ongoing.
How the drugs differ in practice
| Variable | Range across approved drugs |
|---|---|
| Half-life | 13 hours (liraglutide) → 7 days (semaglutide) |
| Dosing frequency | Twice daily → weekly |
| Mechanism | Single GLP-1 → dual GLP-1/GIP → small molecule oral |
| Trial weight loss (top dose) | ~8% (Saxenda) → ~21% (Zepbound) |
| FDA approval | 2005 (Byetta) → 2026 (Foundayo) |
| Form | Injection (most) → oral tablet (Rybelsus, Wegovy oral, Foundayo) |
For the head-to-head comparison of the major weight-loss drugs, see best GLP-1 for weight loss. For mechanism details, see GLP-1 receptor agonists.
How to choose between them
Practical decision factors, in order of impact:
- Indication on label vs your condition. T2D drugs (Ozempic, Mounjaro, Trulicity) are covered differently than weight-only drugs (Wegovy, Zepbound, Saxenda).
- Coverage. What does your insurance cover at what tier?
- Frequency preference. Weekly injection vs daily injection vs daily oral.
- Tolerability profile. Some patients tolerate semaglutide better; some do better on tirzepatide. Trial average masks individual variation.
- Cost. Tied to coverage and savings programs. See GLP-1 cost.
FAQ
How many GLP-1 drugs are FDA-approved? Counting brands, there are over a dozen FDA-approved GLP-1 products across diabetes and weight indications. Counting active molecules, there are seven: semaglutide, tirzepatide, liraglutide, dulaglutide, exenatide, lixisenatide, and orforglipron.
Which is the strongest GLP-1? By average trial weight loss, tirzepatide (Zepbound/Mounjaro) at 15 mg is currently the strongest approved GLP-1 (~21% body weight). The pipeline drug retatrutide has shown higher in Phase 2 but isn't approved.
Is Rybelsus the same as Wegovy? Same molecule (semaglutide), different dose and indication. Rybelsus is oral 3-14 mg approved for diabetes. The newer Wegovy oral (2025) goes to 25 mg and is approved for weight management.
What's the newest GLP-1 drug? Foundayo (orforglipron), approved in 2026 — the first oral small-molecule GLP-1.
Are there generic GLP-1 drugs? Not yet. Brand patents are still in force. Compounded semaglutide and tirzepatide are available through some 503A pharmacies — see compounded GLP-1.
This article is for educational purposes only and is not medical advice. GLP-1 medications are prescription drugs. Discuss any choice with a qualified healthcare professional.